BRAF and melanoma: A joint NCI-SWOG randomised clinical trial evaluating the efficacy of intermittent compared with continuous dosing of dabrafenib and trametinib in patients with V600E mutated-BRAF positive melanoma is ongoing (ClinicalTrials.gov study NCT02196181).